Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants
Sponsor: Deciphera Pharmaceuticals, LLC
Summary
The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of P-glycoprotein (P-gp) substrate (dabigatran) in healthy male participants. This study will last approximately 21 days.
Official title: A Phase 1, Open-label, Fixed-sequence Study to Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants
Key Details
Gender
MALE
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-09
Completion Date
2026-12
Last Updated
2026-09-25
Healthy Volunteers
Yes
Conditions
Interventions
Vimseltinib
Administered orally
Dabigatran
Administered orally
Locations (1)
Dr. Vince Clinical Research
Overland Park, Kansas, United States